Loading clinical trials...
Loading clinical trials...
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
Conditions
Interventions
PEGPH20
Oxaliplatin
+3 more
Locations
154
United States
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States
Alaska Women's Cancer Care
Anchorage, Alaska, United States
Katmai Oncology Group
Anchorage, Alaska, United States
Providence Alaska Medical Center
Anchorage, Alaska, United States
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
Start Date
January 23, 2014
Primary Completion Date
April 1, 2019
Completion Date
November 9, 2023
Last Updated
February 9, 2024
NCT07409272
NCT06998940
NCT06381154
NCT07226856
NCT07344220
NCT01660971
Lead Sponsor
SWOG Cancer Research Network
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions